US 12,472,244 B2
Immunogenic compositions and uses thereof
Maria A. Croyle, Austin, TX (US); and Stephen Clay Schafer, Austin, TX (US)
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed by BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed on May 17, 2024, as Appl. No. 18/667,247.
Application 17/547,901 is a division of application No. 16/941,481, filed on Jul. 28, 2020, granted, now 11,801,295, issued on Oct. 31, 2023.
Application 16/941,481 is a division of application No. 16/392,137, filed on Apr. 23, 2019, granted, now 10,751,409, issued on Aug. 25, 2020.
Application 15/907,259 is a division of application No. 15/081,601, filed on Mar. 25, 2016, granted, now 9,974,850, issued on May 22, 2018.
Application 18/667,247 is a continuation of application No. 18/622,330, filed on Mar. 29, 2024.
Application 18/622,330 is a continuation of application No. 18/476,042, filed on Sep. 27, 2023, granted, now 12,178,868.
Application 18/476,042 is a continuation of application No. 17/547,901, filed on Dec. 10, 2021, abandoned.
Application 16/392,137 is a continuation of application No. 15/907,259, filed on Feb. 27, 2018, granted, now 10,279,029, issued on May 7, 2019.
Claims priority of provisional application 62/137,922, filed on Mar. 25, 2015.
Prior Publication US 2024/0293529 A1, Sep. 5, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); C12N 7/00 (2006.01); C12N 15/88 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 39/39 (2013.01); C12N 7/00 (2013.01); C12N 15/88 (2013.01); A61K 2039/543 (2013.01); A61K 2039/55555 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/10351 (2013.01); C12N 2710/10371 (2013.01); C12N 2760/14134 (2013.01); C12N 2760/16134 (2013.01)] 24 Claims
OG exemplary drawing
 
1. A method for providing an immune response in a mammal, comprising:
obtaining a composition comprising a recombinant viral vector in a pharmaceutically acceptable carrier, said carrier comprising:
(i) PMAL-C16; or
(ii) from about 0.1% to 10% of a zwitterionic surfactant; or
(ii) from about 0.1 to 50 mg/ml of a zwitterionic surfactant; and
administering an effective amount to the composition to a subject;
wherein the subject has been previously exposed to a virus that cross reacts antigenically with the viral vector of the composition.